What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide an update on Elevance Health's (formerly Anthem, Inc.) financial outlook and to furnish information for upcoming discussions with securities analysts and investors scheduled between December 2 and December 7, 2015. It reaffirms the company's full-year 2015 earnings per share guidance.

What are the company's updated financial projections for full-year 2015?

Elevance Health continues to expect GAAP net income for full-year 2015 to be in the range of $9.53 to $9.63 per share. This includes approximately $0.57 per share of net unfavorable items. Excluding these items, the company's adjusted net income outlook remains between $10.10 and $10.20 per share.

What factors are supporting the company's reaffirmed guidance?

The company's reaffirmation of its guidance is supported by the performance of its commercial individual business, which tracked expectations during the third quarter of 2015. The guidance does not include any adjustments beyond those previously reported in the third quarter 2015 earnings release.

What are the key risks mentioned in the filing that could impact future performance?

The filing includes a broad safe harbor statement that highlights numerous risks and uncertainties. These include regulatory changes (like the Affordable Care Act), healthcare cost and utilization trends, the potential outcomes and integration challenges of the Cigna acquisition, competition, risks related to Medicare and Medicaid programs, cybersecurity threats, and general economic conditions.

ELV 8-K: Regulation FD — Nov 20, 2015

Summary

Elevance Health, Inc. (ELV), formerly Anthem, Inc., issued this 8-K filing on November 20, 2015, to provide updated financial guidance and disclose information relevant to upcoming investor and analyst discussions scheduled between December 2-7, 2015. The company reaffirmed its full-year 2015 GAAP net income projection to be in the range of $9.53 to $9.63 per share, which includes approximately $0.57 per share in unfavorable items. Excluding these items, the adjusted net income outlook remains between $10.10 and $10.20 per share. This guidance is supported by the performance of the company's commercial individual business, which met expectations during the third quarter of 2015. The filing also includes a standard safe harbor statement, outlining various risks and uncertainties that could impact future financial results, including those related to regulatory changes, healthcare cost trends, the ongoing acquisition of Cigna Corporation, and operational challenges. Investors should note that this information is provided for context ahead of investor communications and is subject to the forward-looking statements disclaimed within the report.

Key Highlights

1Anthem reaffirmed its full-year 2015 GAAP net income guidance of $9.53-$9.63 per share.
2The company maintained its adjusted net income guidance for full-year 2015 at $10.10-$10.20 per share.
3This guidance includes approximately $0.57 per share of net unfavorable items for the full year.
4The reaffirmation of guidance is supported by the company's commercial individual business meeting expectations in Q3 2015.
5The filing is intended to provide information for upcoming discussions with securities analysts and investors from December 2-7, 2015.
6The report includes a comprehensive safe harbor statement detailing numerous risks and uncertainties that could affect future performance, including regulatory, operational, and acquisition-related factors.
7No adjustments beyond those reported in the Q3 2015 earnings release are included in this guidance.

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Nov 20, 2015)

Summary

Key Highlights

Frequently Asked Questions